English
Regional settings| Spread | 0.1260 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ £5,000.00 Short position overnight fee ~ £4,000.00 | -0.025295% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ £5,000.00 Short position overnight fee ~ £4,000.00 | 0.003377% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | GBP | ||||
| Min traded quantity | 0.1 | ||||
| Margin | 20 | ||||
| Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 14.3265 |
| Open | 14.177 |
| 1-Year Change | -7.01% |
| Day's Range | 13.987 - 14.177 |
Indivior PLC is a United Kingdom-based pharmaceutical company. The Company is engaged in developing medicines to treat addiction and serious mental illnesses. It focuses to build a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and cooccurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as new therapies to address the needs of people suffering from alcohol, stimulant and cannabis use disorders. Its pipeline products include INDV-3000 - Selective Dopamine D3-receptor Antagonist, RBP-6000 - Buprenorphine XR injection, Buprenorphine/ Naloxone Sublingual Film, Buprenorphine/ Naloxone Sublingual Tablet and Buprenorphine Sublingual Tablet, among others. Its portfolio of products is available in more than 40 countries.
BRIEF: For the fiscal year ended 31 December 2021, Indivior PLC revenues increased 22% to $791M. Net income totaled $205M vs. loss of $148M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Other operating income increase from $0K to $32M (income), Selling/General/Admin. Expense, decrease of 5% to $192M (expense).
